References

1. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States. Arch Dermatol. 2007;143(7):854-859.
2. CTCL-MF fast facts. Cutaneous Lymphoma Foundation Web site.
   http://www.clfoundation.org/about_cutaneous_lymphoma/CL_fast_facts.htm.
3. Cutaneous T-cell lymphoma. The Lymphoma & Leukemia Society. http://leukemia-lymphoma.org/attachments/National/br_1163608564.pdf. Accessed September 18, 2009.
4. Data on file, Therakos, Inc.
5. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med. 1987;316(6):297-303.
6. Geskin LJ, Foss F, Duvic M, et al. Efficacy of extracorporeal photopheresis (ECP) monotherapy in the treatment of cutaneous T-cell lymphoma. Poster presented at: The American Society of Hematology 49th Annual Meeting and Exposition; December 8-11, 2007; Atlanta, GA. Abstract 2561.
7. McCann SA. Cutaneous T-cell lymphoma: overview and nursing perspectives. Nurs Clin North Am. 2007;42(3):421-455, vi-vii.
8. McKenna KE, Whittaker S, Rhodes LE, et al; British Photodermatology Group; U.K. Skin Lymphoma Group. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol. 2006;154(1):7-20.
9. Mycosis fungoides and Sézary syndrome Treatment. National Cancer Institute Web site. http://www.cancer.gov.
10. Mycosis fungoides/Sézary syndrome. In: NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas. v.1.2009. Fort Washington, PA: National Comprehensive Cancer Network; 2009:MFSS-1-MFSS-B.2.:70.
11. Suchin KR, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol. 1999;41(6):980-986.
12. THERAKOS™ CELLEX™ Photopheresis System Operator's Manual. Rev. 3.0-1460436.
13. UVADEX^® (methoxsalen) Sterile Solution Prescribing Information. Manufactured by Ben Venue Laboratories, Bedford, OH 44146-0568 for Therakos, Inc, a Johnson & Johnson Company, Exton, PA, 19341.
14. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
15. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology. 2009. www.nccn.org. Accessed September 18, 2009.
16. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008;112(7):2667-74
17. Bisaccia E, Palangio M, Gonzalez J, et al.Treatment of extensive chronic graft-versus-host disease with extracorporeal photochemotherapy. J Clin Apher. 2006;21(3):181-7.
18. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35(12):1187-93.
19. Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107(8):3074-80.
20. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998;92(9):3098-104
21. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant. 2010;29(4):424-31.
22. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med. 1998;339:1744–1751.
23. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. 2006;21(1):72-7.
24. European Federation of Pharmaceutical Industries and Associations. Mycosis Fungoides. Medicines for Mankind 2006;4:54-6.
25. Declaration of Conformity
26. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. J Heart Lung Transplant 2006;25:283-8.
27. O’Hagan AR, Stillwell PC, Arroliga A, et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest 1999;115:1459-62.
28. Lehrer MS, Ruchelli E, Olthoff KM, et al. Successful reversal of recalcitrant hepatic allograft rejection by photopheresis. Liver Transpl 2000;6:644-7.
29. Urbani L, Mazzoni A, Catalano G, et al. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. Transplant Proc 2004;36:3068-70.
30. Genberg H, Kumlien G, Shanwell A, et al. Refractory acute renal allograft rejection successfully treated with photopheresis. Transplant Proc 2005;37:3288-9.
31. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. J Thorac Cardiovasc Surg 1999;117:1063-9.
32. Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. Ann Transplant 2000;5:44-7.
33. Operators Manual
34. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56.
35. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-17.
36. McKenna KE, Whittaker S, Rhodes LE, et al. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group. Br J Dermatol. 2006 Jan;154(1):7-20.
37. Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000;96:2426-2431.
38. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006 Mar;91(3):405-8.
39. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008 Nov;42(9):609-17.
40. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003;31:459-65.
41. Opinion given by an expert clinician speaking at the 'Leaders of Photopheresis' meeting, Kensington Hilton, London, June 2009. The views expressed at this meeting do not necessarily reflect the views of THERAKOS, Inc.
42. Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008 Apr;158(4):659-78. Epub 2008 Jan 30.
43. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant 1992;11:746–750.
44. Costanzo-Nordin MR, Hubbell EA, O’Sullivan EJ, et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection: preliminary clinical report. Circulation 1992;86:II242–250.
45. Meiser BM, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation 1994;57:563–568.
46. Dall’Amico R, Livi U, Milano A, et al. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995;60:45–49.
47. Giunti G, Schurfeld K, Maccherini M, et al. Photopheresis for recurrent acute rejection in cardiac transplantation. Transplant Proc 1999;31:128–129.
48. Dall’Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organs 2000; 23:49–54.
49. Lehrer MS, Rook AH, Tomaszewski JE, et al. Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J Heart Lung Transplant. 2001;20:1233-1236
50. Barr ML, Baker CJ, Schenkel FA, et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000;14:162–166.
51. Slovis BS, Loyd JE, King LE Jr. Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995;332:962.
52. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. Transplantation. 2008 Dec 15;86(11):1625-7.
53. Kumlien G, Genberg H, Shanwell A, et al. Photopheresis for the treatment of refractory renal graft rejection. Transplantation. 2005;79:123–125.
54. Dall’Amico R, Murer L, Montini G, et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. J Am Soc Nephrol 1998;9:121–127.